New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study

Isabel Aguilar-Palacio, María José Rabanaque, Lina Maldonado, Armando Chaure, José María Abad-Díez, Montse León-Latre, José Antonio Casasnovas and Sara Malo
Additional contact information
Isabel Aguilar-Palacio: Department of Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain
María José Rabanaque: Department of Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain
Lina Maldonado: Department of Economic Structure, Economic History and Public Economics, University of Zaragoza, 50005 Zaragoza, Spain
Armando Chaure: GRISSA Research Group, 50009 Zaragoza, Spain
José María Abad-Díez: GRISSA Research Group, 50009 Zaragoza, Spain
Montse León-Latre: Fundación Instituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain
José Antonio Casasnovas: Fundación Instituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain
Sara Malo: Department of Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain

IJERPH, 2020, vol. 17, issue 20, 1-13

Abstract: The objective of this study was to analyse persistence to lipid-lowering drug use for primary prevention of cardiovascular disease (CVD) in a new users cohort, to explore all-cause and cardiovascular related morbidity, comorbidity and mortality in this group and, finally, to study the relationship between persistence and morbimortality. We selected subjects who started lipid-lowering treatment for primary prevention of CVD between 1 January 2010 and 31 December 2017 (N = 1424), and classified them as treatment-persistent or -nonpersistent. Bivariate analyses were performed to compare sociodemographic and clinical variables, morbimortality and time to event between groups. The association between morbidities was explored using comorbidity network analysis. The effect of persistence was analysed using logistic regression and Cox survival analyses. Only 38.7% of users were persistent with treatment. Persistent and nonpersistent users had similar sociodemographic and clinical profiles, although differed in age, smoking status, and glycemia. Comorbidity networks revealed that the number of co-occurring diagnoses was higher in nonpersistent than persistent users. Adjusted analyses indicated a protective effect of treatment persistence, especially against major adverse cardiovascular events (MACE), but this effect was not statistically significant. Observational studies are crucial to characterize real-world effectiveness.

Keywords: lipid-lowering drugs; persistence; major adverse cardiovascular event (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/20/7653/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/20/7653/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:20:p:7653-:d:431873

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().